Arlene Siefker-Radtke

May 6, 2024 | brnw.ch | Arlene Siefker-Radtke

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses toxicities associated with the combination of enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda) in patients with metastatic bladder cancer. Enfortumab vedotin combined with pembrolizumab carries a boxed warning due to the risk of Stevens-Johnson Syndrome, which is a severe skin reaction, Siefker-Radtke begins.

May 6, 2024 | onclive.com | Arlene Siefker-Radtke

May 6, 2024Arlene O. Siefker-Radtke, MD, discusses toxicities associated with enfortumab vedotin plus pembrolizumab in patients with bladder cancer. Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses toxicities associated with the combination of enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda) in patients with metastatic bladder cancer.

May 3, 2024 | targetedonc.com | Arlene Siefker-Radtke

Arlene O. Siefker-Radtke, MD, professor of genitourinary medical oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses the latest breakthroughs in bladder cancer treatment with erdafitinib (Balversa), an FGFR1-4 inhibitor. The agent was recently approved by the FDA for the treatment of locally advanced or metastatic urothelial carcinoma with FGFR3 alterations with disease progression following a prior line of treatment.

Mar 25, 2024 | targetedonc.com | Arlene Siefker-Radtke

Arlene O. Siefker-Radtke, MD, professor of genitourinary medical oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, dives into the background and the cohorts included in the phase 3 THOR study (NCT03390504) which evaluated erdafitinib (Balversa) vs pembrolizumab (Keytruda) in pretreated patients with advanced or metastatic urothelial cancer with select fibroblast growth factor receptor (FGFR) alterations.

Feb 23, 2024 | urotoday.com | Arlene Siefker-Radtke

Read the Full Video TranscriptSam Chang: Hello everyone. My name is Sam Chang. I'm a urologist in Nashville, Tennessee, and I work at Vanderbilt University Medical Center. We're quite fortunate to have Dr. Arlene Siefker-Radtke, who's a professor and leads a program in urethral carcinoma and bladder cancer at the MD Anderson Cancer Center in Texas.